Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,739 | 3 | 88.0% |
| Unspecified | $236.62 | 1 | 12.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $1,976 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $236.62 | 1 | F. Hoffmann-La Roche AG ($236.62) |
| 2018 | $1,739 | 3 | F. Hoffmann-La Roche AG ($1,739) |
All Payment Transactions
4 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/31/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $236.62 | Research |
| Study: A phase 1b, open-label, dose-escalation study of the safety and pharmacology of GDC-0068 in combination with docetaxel, fluoropyrimidine plus oxaliplatin, paclitaxel, or enzalutamide in patients with advanced solid tumors • Category: None | ||||||
| 12/31/2018 | F. Hoffmann-La Roche AG | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $881.93 | General |
| 06/30/2018 | F. Hoffmann-La Roche AG | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $474.99 | General |
| 06/30/2018 | F. Hoffmann-La Roche AG | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $382.06 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A phase 1b, open-label, dose-escalation study of the safety and pharmacology of GDC-0068 in combination with docetaxel, fluoropyrimidine plus oxaliplatin, paclitaxel, or enzalutamide in patients with advanced solid tumors | F. Hoffmann-La Roche AG | $236.62 | 1 |
About Dr. Daniel Maslyar, MD
Dr. Daniel Maslyar, MD is a Hematology & Oncology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508975459.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Maslyar, MD has received a total of $1,976 in payments from pharmaceutical and medical device companies, with $236.62 received in 2020. These payments were reported across 4 transactions from 1 company. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1,739).
Practice Information
- Specialty Hematology & Oncology
- Location San Francisco, CA
- Active Since 08/30/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1508975459
Products in Payments
- Non-Covered Product (Drug) $236.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in San Francisco
Dr. Terence Friedlander, Ms, MS
Hematology & Oncology — Payments: $248,592
Pamela Munster, Md, MD
Hematology & Oncology — Payments: $98,260
Dr. Caroline Behler, M.d., M.s, M.D., M.S
Hematology & Oncology — Payments: $64,653
David Oh
Hematology & Oncology — Payments: $57,997
Dr. Paul Volberding, Md, MD
Hematology & Oncology — Payments: $51,997
Dr. Alain Algazi, M.d, M.D
Hematology & Oncology — Payments: $24,175